Industries > Pharma > Real-World Evidence (RWE) Solutions Market Report 2020-2030

Real-World Evidence (RWE) Solutions Market Report 2020-2030

Forecasts by Component (Data Sets, Services), Datasets (Clinical Settings Data, Claims Data, Pharmacy Data, Patient-Powered Data, Others), Therapeutic Area (Oncology, Cardiovascular Diseases, Neurology, Immunology, Other Therapeutic Areas), End-users (Healthcare Payers, Healthcare Providers, Pharmaceutical & Medical Device Companies, Other End-users), by Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa), PLUS COVID-19 Recovery Scenarios and Profiles of Leading Real-World Evidence Solutions Companies

PUBLISHED: 01 October 2020
PAGES: 277
PRODUCT CODE: PHA0928

Clear
WOOCS 2.2.1
SKU: PHA0928 Categories: , Tag:

Real-world evidence (RWE) will be essential in beating COVID-19. Patients, vaccine recipients, healthcare workers – Real-World data needs to be gathered to guide treatment decisions, risk-assessments, and standards of care and practice.

RWE is essential NOW. You must read this report – today. RWE offers you a treatment roadmap – read this report to discover how.

This report includes data analysis and invaluable insight into how COVID-19 will affect your industry. Access this report immediately.

Drivers
• Increasing us of big Data in Healthcare
• Growing use of smart wearables, sensors, and devices which collect real world data
• Usage of RWE in biopharma
• RWE can enhance clinical trials as seen in COVID-19 work

Restraints
• Patient privacy issue
• Lack of adequate financing and high capital investment

Opportunities
• Increasing use of patient centric programs
• Long term outlook for chronic disease management

This report tells you how to stay ahead
• Unique 270+ page report – delivers 350+ tables and charts/graphs.
• Find out the most lucrative areas in the industry and the future market prospects.
• Delivers forecasted sales at overall world market, regional and country level.
• Gives you financial results, trends, opportunities, and revenue predictions.
• Shows you the opportunities in this growing Real-World Evidence Market and how to exploit them.

To access the data contained in this document please email contactus@visiongain.com

Forecasts to 2030 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2030, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), SWOT Analysis, product profiles and commercial developments.

UNIQUE COVID-19 VARIATIONS – only available in this Visiongain report are dedicated analysis of 4 different rebound scenarios of how the market will develop – no matter how COVID-19 effects the economy.

Discover sales predictions for the world market and submarkets

By Component
• Data Sets
• Services

By Datasets
• Clinical Settings Data
• Claims Data
• Pharmacy Data
• Patient-Powered Data
• Others

By Therapeutic Area
• Oncology
• Cardiovascular Diseases
• Neurology
• Immunology
• Other Therapeutic Areas

By End-Users
• Healthcare Payers
• Healthcare Providers
• Pharmaceutical & Medical Device Companies
• Other End-Users

CTA

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 4 regional and 10 leading national markets:

By Region

• North America
• U.S.
• Canada

• Europe
• Germany
• France
• UK
• Italy
• Spain
• Rest of Europe

• Asia Pacific
• China
• Japan
• India
• Rest of Asia Pacific

• RoW

Real-World Evidence (RWE) Solutions Market Report 2020-2030

Need industry data? Please contact us today.

Leading companies and the potential for market growth
Overall world revenue for Real-World Evidence Market will surpass $xx million in 2020, our work calculates. We predict strong revenue growth through to 2030. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How the Real-World Evidence Market report helps you
In summary, our 270+ page report provides you with the following knowledge:

• Revenue forecasts to 2030 for Real-World Evidence Market, with forecasts for xx, each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues

• Revenue forecasts to 2030 for 5 regional and xx key national markets – See forecasts for the Real-World Evidence market in North America, Europe, Asia-Pacific and Rest of the World. Also forecasted is the market in the US, Canada, Brazil, Germany, France, UK, Italy, Spain, China, India, and Japan, among other prominent economies.

• Prospects for established firms and those seeking to enter the market– including company profiles for 13 of the major companies involved in the Real-World Evidence Market. Some of the company’s profiled in this report include:
• Iqvia
• IBM
• Pharmaceutical Product Development
• PAREXEL
• Optum (A Subsidiary of United Health Group, Inc.)
• PerkinElmer
• Icon PLC
• Oracle
• Cognizant
• Syneos Health
• Anthem
• Clinigen
• Covance Inc.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Real-World Evidence Market and leading companies. You will find data, trends and predictions.

To access the data contained in this document please email contactus@visiongain.com

Buy our report today Real-World Evidence (RWE) Solutions Market Report 2020-2030: Forecasts by Component (Data Sets, Services), Datasets (Clinical Settings Data, Claims Data, Pharmacy Data, Patient-Powered Data, Others), Therapeutic Area (Oncology, Cardiovascular Diseases, Neurology, Immunology, Other Therapeutic Areas), End-users (Healthcare Payers, Healthcare Providers, Pharmaceutical & Medical Device Companies, Other End-users), by Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa), PLUS COVID-19 Recovery Scenarios and Profiles of Leading Real-World Evidence Solutions Companies. Avoid missing out by staying informed – order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for Real-World Evidence (RWE) Solutions Market Report 2020-2030


Download sample pages

Complete the form below to download your free sample pages for Real-World Evidence (RWE) Solutions Market Report 2020-2030


Latest Pharma news

Visiongain Publishes Pharmaceutical Product Information Management System Market Report 2020-2030

Some of the major factors fuelling the growth of global market include significant advantages associated with PIM solutions and inclination towards centralized models among across pharma sector.

19 October 2020

READ

Visiongain Publishes Pulmonary/Respiratory Drug Delivery Market Report 2020-2030

The coronavirus outbreak has negatively impacted all the economies and industries across the globe. Hence, for the next 1-2 years, the global respiratory drug delivery market is expected to take a hit.

12 October 2020

READ

Visiongain Publishes Real-World Evidence (RWE) Solutions Market Report 2020-2030

We predict strong revenue growth through to 2030. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

02 October 2020

READ

Visiongain Publishes mRNA Vaccines Market Report 2021-2031

The development of mRNA vaccines is driven by new biotechnologies and nanotechnologies. Emerging delivery technologies, such as electroporation (EP), innovative vaccine formats like mRNA preventive boost, and new molecular adjuvant technologies are particularly important for mRNA vaccines reaching their potential.

02 October 2020

READ

Categories

Category